Previous studies suggested that dysregulated SATB1 expression is involved in CTCL progression: low SATB1 was associated with an impaired prognosis, although SATB1 expression did not correlate with MF stages in all studies [32]. This evidence concerns the gene SATB1 and primary cutaneous T-cell non-Hodgkin lymphoma.